What's new? Log in Free sign up

RedHill Biopharma (RDHL)

Company Profile

Company profile

Ticker

RDHL

Exchange

Website

www.redhillbio.com

CEO

Mr. Dror Ben-Asher

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

GENETIC TECHNOLOGIES LTD /FI

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Subsidiaries Lists

RDHL stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

CVI Investments, Inc.

INTRACOASTAL CAPITAL, LLC

CVI Investments, Inc.

Empery Asset Management, LP

SABBY MANAGEMENT, LLC

Empery Asset Management, LP

SABBY MANAGEMENT, LLC

Cosmo Pharmaceuticals N.V.

Ibex Investors LLC

Ibex Investors LLC

Financial summary

Financial statements Chart RDHL financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2024

RDHL institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	21	20	+5.0%
Opened positions	3	18	-83.3%
Closed positions	2	0	NEW
Increased positions	5	0	NEW
Reduced positions	5	0	NEW

13F shares	Current	Prev Q	Change
Total value	10.13 bn	10.82 bn	-6.3%
Total shares	703.84 mm	704.55 mm	-0.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
CVI Investments	700.00 mm	$9.41 bn	0.0%
Sabby Management	1.34 mm	$497.18 mm	-42.2%
Intracoastal Capital	1.25 mm	$16.80 mm	0.0%
Empery Asset Management	647.82 k	$0.00	0.0%
UBS UBS	142.39 k	$52.83 mm	+181.4%
Gagnon Securities	116.02 k	$43.01 mm	-2.0%
Citadel Advisors	108.57 k	$40.25 mm	NEW
Federation des caisses Desjardins du Quebec	99.88 k	$37.05 mm	+27.5%
Jane Street	47.14 k	$17.26 mm	NEW
Virtu Financial	37.11 k	$14.00 k	+75.3%

Largest transactions	Shares	Bought/sold	Change
Sabby Management	1.34 mm	-978.05 k	-42.2%
Citadel Advisors	108.57 k	+108.57 k	NEW
UBS UBS	142.39 k	+91.79 k	+181.4%
Jane Street	47.14 k	+47.14 k	NEW
Federation des caisses Desjardins du Quebec	99.88 k	+21.52 k	+27.5%
Virtu Financial	37.11 k	+15.94 k	+75.3%
Rhumbline Advisers	18.93 k	-11.26 k	-37.3%
Gagnon Securities	116.02 k	-2.34 k	-2.0%
Two Sigma Securities	13.03 k	+1.48 k	+12.8%
Aspire Private Capital	0.00	-406.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

RedHill Biopharma's Opaganib Demonstrates Protective Activity Against GI-ARS, Paving The Way for Future FDA Approval vVa Animal Rule

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological

RedHill Biopharma Announced Results From New In Vivo Studies Of Opaganib For Gastrointestinal Acute Radiation Syndrome, Undertaken As Part Of The U.S. Government's Radiation And Nuclear Countermeasures Program Contract That Further Confirms Opaganib's Protective Activity In Animal Models

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological

Redhill Biopharma Has Been Awarded Approximately $8M Plus Costs In A Summary Judgment By The Supreme Court Of The State Of New York, New York County, In Its Legal Proceedings Against South Korea-based Kukbo

Press releases

From Benzinga Pro

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization The

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit

Detroit, Michigan--News Direct--By Meg Flippin, BenzingaRedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, won a significant legal and financial victory, announcing a summary judgment in its

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.